On July 23, 2026, a Phase 3 clinical trial of retatrutide (LY3437943) was listed with an active, not recruiting status. The study is titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain."
The trial is registered under identifier NCT07035093 and is being conducted in the Phase 3 stage of clinical development. Its listed status indicates that participant enrollment is no longer ongoing, while the study itself continues.
No results have been posted for this trial as part of this update. The listing reflects only the trial's phase, title, and current recruitment status as of the stated date. No outcome data, safety findings, or efficacy conclusions are included in this update.
Readers should note that this information reflects only the administrative status of the trial registration and does not describe any study findings. For additional background on retatrutide, including its regulatory status and general information, readers can consult the compound overview.